Mayo Clinic SPORE in Pancreatic Cancer

拟议中的胰腺癌梅奥诊所孢子将促进和促进胰腺癌的研究，这很可能使目前希望非常渺茫或治疗选择非常渺茫的患者受益。由于对胰腺癌研究的缺乏，我们的重点是发现新的机制和途径，以阐明胰腺癌的病因和发病机制，进而转化为预防、早期发现和治疗的策略。在资深胰腺癌研究人员的带领下，我们的孢子拥有重要的研究和患者基础。梅奥诊所的医生每年看大约450名胰腺癌患者，仅占胰腺癌患者总数的1.5% 美国的癌症病例。所有提议的项目都有科学基础和翻译轨迹。项目1将为研究候选基因和环境在胰腺癌病因学中的作用提供最明确的手段之一。项目2将包括一项回顾性队列研究，以确定筛查患有未确诊胰腺癌的糖尿病患者的最佳标准，并确定区分明显由胰腺癌引起的糖尿病患者的标记物。项目3将研究Vav1原癌基因在胰腺癌中的作用机制。项目4将研究BRCA2基因在胰腺癌中的作用机制和作用。项目5将利用胰腺癌的转基因动物模型来评估疫苗、COX-2抑制剂和化疗/放射的治疗组合。我们将特别努力鼓励利用核心资源了解胰腺癌的先导性研究。经过正式、严格的审查程序后，该孢子每年将资助多达六个发展项目。我们将支持初级教师的职业发展，他们将被期望在转化性胰腺癌研究中建立独立的项目。四个核心(管理核心、患者登记和生物样本核心、动物模型和异种移植核心、以及生物统计核心)将支持研究项目。外部咨询委员会和内部科学咨询委员会将提供科学投入和指导，广泛的机构支持将加强这一孢子的基础设施。

The proposed Mayo Clinic SPORE in Pancreatic Cancer will facilitate and promote research in pancreatic cancer that is highly likely to result in benefit to patients who currently have very little hope or treatment options. With a paucity of research in pancreatic cancer, our emphasis is on the discovery of novel mechanisms and pathways that will elucidate the etiology and pathogenesis of pancreatic carcinoma, which in turn can translate into strategies for prevention, early detection, and treatment. Led by senior pancreatic cancer researchers, our SPORE has a significant research and patient base. Annually, physicians at Mayo Clinic see approximately 450 patients with pancreatic cancer, which alone constitutes 1.5% of all pancreatic cancer cases in the United States. All of the proposed projects have a scientific base with a translational trajectory. Project #1 will provide one of the most definitive means to study the role of candidate genes and environment in the etiology of pancreatic adenocarcinoma. Project #2 will include both a retrospective cohort study to characterize the optimal criteria for screening diabetic patients with undiagnosed pancreatic cancer and identify markers that discriminate patients with diabetes mellitus that is apparently caused by pancreatic cancer. Project #3 will examine the mechanisms of action and role of Vavl protooncogene in pancreatic cancer. Project #4 will examine the role of the mechanism and role of the BRCA2 gene in pancreatic cancer. Project #5 will utilize transgenic animal models of pancreatic cancer to evaluate therapeutic combinations of vaccine, COX-2 inhibitors, and chemo/radiation. We will make particular efforts to encourage pilot studies that utilize the core resources to understand pancreatic cancer. Following a formal, rigorous review process, this SPORE will thus fund up to six developmental projects annually. We will support career development of junior faculty who will be expected to build independent programs in translational pancreatic cancer research. Four cores Administrative Core, Patient Registry and Biospecimens Core, Animal Models and Xenograft Core, and Biostatistics Core) will support the research projects. An External Advisory Committee and internal Scientific Advisory Committee will provide scientific input and guidance, and broad institutional support will enhance the infrastructure of this SPORE.